{"id":30903,"date":"2023-12-15T10:04:21","date_gmt":"2023-12-15T09:04:21","guid":{"rendered":"https:\/\/www.mgc.es\/?p=30903"},"modified":"2023-12-13T10:51:47","modified_gmt":"2023-12-13T09:51:47","slug":"amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil","status":"publish","type":"post","link":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/","title":{"rendered":"Amira i la Fundaci\u00f3 MGC avancen en la investigaci\u00f3 del c\u00e0ncer infantil"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_1 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\"><p class=\"ez-toc-title\" style=\"cursor:inherit\">\u00cdndex de continguts<\/p>\n<\/div><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/#El_sarcoma_de_teixits_tous\" >El sarcoma de teixits tous<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/#Acord_amb_la_Fundacio_MGC\" >Acord amb la Fundaci\u00f3 MGC<\/a><\/li><\/ul><\/nav><\/div>\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"880\" height=\"486\" src=\"https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil-880x486.jpg\" alt=\"\" class=\"wp-image-30901\" srcset=\"https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil-880x486.jpg 880w, https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil-440x243.jpg 440w, https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil-768x424.jpg 768w, https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil.jpg 1000w\" sizes=\"auto, (max-width: 880px) 100vw, 880px\" \/><\/figure>\n\n\n\n<p><a href=\"https:\/\/amiratx.com\/\">Amira Therapeutics<\/a>, participada per la Fundaci\u00f3 MGC, rep l\u2019autoritzaci\u00f3 de l\u2019Ag\u00e8ncia Europea de Medicaments per al tractament del sarcoma de teixits tous.<\/p>\n\n\n\n<p><strong>Amira<\/strong>, una biotecnol\u00f2gica innovadora dedicada a millorar la vida de pacients pedi\u00e0trics amb c\u00e0ncer i les seves fam\u00edlies, amb qu\u00e8 la <strong>Fundaci\u00f3 MGC<\/strong> participa mitjan\u00e7ant un acord d&#8217;inversi\u00f3, anuncia amb orgull que <strong>l&#8217;Ag\u00e8ncia Europea de Medicaments<\/strong> (EMA) ha atorgat la designaci\u00f3 de medicament orfe al seu compost AMI463 per al <strong>tractament del sarcoma de teixits tous<\/strong>. Aquesta fita crucial subratlla el comprom\u00eds d&#8217;abordar les necessitats no satisfetes en <strong>oncologia pedi\u00e0trica<\/strong>.<\/p>\n\n\n\n<p>La designaci\u00f3 de medicament orfe s&#8217;atorga a tractaments prometedors per a malalties rares dins de la Uni\u00f3 Europea, oferint beneficis com l\u2019assist\u00e8ncia en protocols, exclusivitat de mercat durant deu anys i reduccions de tarifes. Els medicaments pedi\u00e0trics poden rebre dos anys addicionals d&#8217;exclusivitat de mercat, impulsant encara m\u00e9s els esfor\u00e7os d&#8217;Amira per <strong>portar AMI463 als pacients que ho necessiten<\/strong>.<\/p>\n\n\n\n<p>A m\u00e9s del progr\u00e9s a la UE, Amira ha iniciat el proc\u00e9s per <strong>estendre aquesta designaci\u00f3 a l&#8217;Administraci\u00f3 d&#8217;Aliments i Medicaments dels Estats Units<\/strong> (FDA) i sol\u00b7licitar la designaci\u00f3 de malaltia pedi\u00e0trica rara. Aquest pas \u00e9s el comprom\u00eds d&#8217;expandir l&#8217;abast dels tractaments innovadors i <strong>abordar el desafiament global del c\u00e0ncer pedi\u00e0tric<\/strong>.<\/p>\n\n\n\n<p>Sergi P\u00e9rez, CEO d&#8217;Amira Therapeutics, va comentar sobre aquest \u00e8xit: &#8220;El nostre viatge a Amira Therapeutics est\u00e0 impulsat per una visi\u00f3 singular: transformar el panorama de l&#8217;oncologia pedi\u00e0trica. La designaci\u00f3 de medicament orfe per a AMI463 no \u00e9s nom\u00e9s una fita reguladora; \u00e9s far d&#8217;esperan\u00e7a per a les fam\u00edlies i els nens afectats per c\u00e0ncers rars. Junts, amb els nostres socis i la comunitat m\u00e8dica, ens dediquem a fer que cada dia compti en la lluita contra el c\u00e0ncer pedi\u00e0tric.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"El_sarcoma_de_teixits_tous\"><\/span><strong>El sarcoma de teixits tous<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El sarcoma de teixits tous, un grup rar i divers de tumors derivats de teixits connectius mesenquimals embrionaris, sovint comporta un mal pron\u00f2stic, amb limitades opcions de tractament m\u00e9s enll\u00e0 de la quimioter\u00e0pia. Amira, una iniciativa del <a href=\"https:\/\/www.leitat.org\/\">Centre Tecnol\u00f2gic Leitat<\/a>, est\u00e0 a l&#8217;avantguarda del desenvolupament d&#8217;AMI463, especialment per al rabdomiosarcoma, el sarcoma de teixits tous m\u00e9s com\u00fa en nens. El rabdomiosarcoma, que afecta aproximadament 400 pacients menors de 18 anys anualment a Europa, \u00e9s un c\u00e0ncer relacionat amb els m\u00fasculs, caracteritzat per una activaci\u00f3 de la via de senyalitzaci\u00f3 Hedgehog, que afecta principalment els teixits musculars i els \u00f2rgans buits.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Acord_amb_la_Fundacio_MGC\"><\/span><strong>Acord amb la Fundaci\u00f3 MGC<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Amira Therapeutics est\u00e0 profundament compromesa amb els esfor\u00e7os per col\u00b7laborar amb la societat en general, com s&#8217;exemplifica a l&#8217;acord recentment signat amb la Fundaci\u00f3 MGC, amb qui comparteix la seva dedicaci\u00f3 per combatre el c\u00e0ncer pedi\u00e0tric.<\/p>\n\n\n\n<p>La Fundaci\u00f3 MGC, fidel als seus objectius fundacionals com \u00e9s el seu suport a l&#8217;\u00e0mbit de la investigaci\u00f3 biom\u00e8dica, va signar el mes d&#8217;octubre passat un acord d&#8217;inversi\u00f3 per a aquesta investigaci\u00f3 en f\u00e0rmacs contra el c\u00e0ncer infantil en aquest projecte promogut per Leitat. L&#8217;acord preveu la possibilitat, per part de la Fundaci\u00f3 MGC, d&#8217;assolir una participaci\u00f3 del 15% del capital d&#8217;Amira Therapeutics, <em>spin-off<\/em> de Leitat especialitzada en aquest tipus d&#8217;\u00e0mbits terap\u00e8utics.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amira Therapeutics, participada per la Fundaci\u00f3 MGC, rep l\u2019autoritzaci\u00f3 de l\u2019Agencia Europea de Medicaments per al tractament del sarcoma de teixits tous.<\/p>\n","protected":false},"author":3,"featured_media":30901,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[432],"class_list":["post-30903","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualitat","tag-fundacio-mutua-general-de-catalunya"],"featured_image_src":"https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil.jpg","author_info":{"display_name":"Revista Inter\u00e8s Mutu","author_link":"https:\/\/www.mgc.es\/ca\/blog\/author\/interesmutu\/"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amira i la Fundaci\u00f3 MGC avancen en la investigaci\u00f3 del c\u00e0ncer infantil - MGC M\u00fatua<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amira i la Fundaci\u00f3 MGC avancen en la investigaci\u00f3 del c\u00e0ncer infantil - MGC M\u00fatua\" \/>\n<meta property=\"og:description\" content=\"Amira Therapeutics, participada per la Fundaci\u00f3 MGC, rep l\u2019autoritzaci\u00f3 de l\u2019Agencia Europea de Medicaments per al tractament del sarcoma de teixits tous.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/\" \/>\n<meta property=\"og:site_name\" content=\"MGC M\u00fatua\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/mgcmutua\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-15T09:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"552\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Revista Inter\u00e8s Mutu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@mgcmutua\" \/>\n<meta name=\"twitter:site\" content=\"@mgcmutua\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Revista Inter\u00e8s Mutu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amira i la Fundaci\u00f3 MGC avancen en la investigaci\u00f3 del c\u00e0ncer infantil - MGC M\u00fatua","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/","og_locale":"ca_ES","og_type":"article","og_title":"Amira i la Fundaci\u00f3 MGC avancen en la investigaci\u00f3 del c\u00e0ncer infantil - MGC M\u00fatua","og_description":"Amira Therapeutics, participada per la Fundaci\u00f3 MGC, rep l\u2019autoritzaci\u00f3 de l\u2019Agencia Europea de Medicaments per al tractament del sarcoma de teixits tous.","og_url":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/","og_site_name":"MGC M\u00fatua","article_publisher":"https:\/\/www.facebook.com\/mgcmutua","article_published_time":"2023-12-15T09:04:21+00:00","og_image":[{"width":1000,"height":552,"url":"https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil.jpg","type":"image\/jpeg"}],"author":"Revista Inter\u00e8s Mutu","twitter_card":"summary_large_image","twitter_creator":"@mgcmutua","twitter_site":"@mgcmutua","twitter_misc":{"Escrit per":"Revista Inter\u00e8s Mutu","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["Article","BlogPosting"],"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/#article","isPartOf":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/"},"author":{"name":"Revista Inter\u00e8s Mutu","@id":"https:\/\/www.mgc.es\/#\/schema\/person\/010c961d9c9acf38f11187a02b646c16"},"headline":"Amira i la Fundaci\u00f3 MGC avancen en la investigaci\u00f3 del c\u00e0ncer infantil","datePublished":"2023-12-15T09:04:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/"},"wordCount":560,"publisher":{"@id":"https:\/\/www.mgc.es\/#organization"},"image":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil.jpg","keywords":["fundaci\u00f3 m\u00fatua general de catalunya"],"articleSection":["Actualitat M\u00fatua"],"inLanguage":"ca"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/","url":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/","name":"Amira i la Fundaci\u00f3 MGC avancen en la investigaci\u00f3 del c\u00e0ncer infantil - MGC M\u00fatua","isPartOf":{"@id":"https:\/\/www.mgc.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/#primaryimage"},"image":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil.jpg","datePublished":"2023-12-15T09:04:21+00:00","breadcrumb":{"@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/#primaryimage","url":"https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil.jpg","contentUrl":"https:\/\/www.mgc.es\/wp-content\/uploads\/2023\/12\/cancer-infantil.jpg","width":1000,"height":552},{"@type":"BreadcrumbList","@id":"https:\/\/www.mgc.es\/ca\/blog\/amira-i-la-fundacio-mgc-avancen-en-la-investigacio-del-cancer-infantil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mgc.es\/ca\/"},{"@type":"ListItem","position":2,"name":"Amira i la Fundaci\u00f3 MGC avancen en la investigaci\u00f3 del c\u00e0ncer infantil"}]},{"@type":"WebSite","@id":"https:\/\/www.mgc.es\/#website","url":"https:\/\/www.mgc.es\/","name":"MGC M\u00fatua","description":"MGC M\u00fatua \u00e9s una entitat asseguradora sense \u00e0nim de lucre constitu\u00efda al 1982 i especialitzada en assegurances de salut i assist\u00e8ncia.","publisher":{"@id":"https:\/\/www.mgc.es\/#organization"},"alternateName":"MGC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mgc.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.mgc.es\/#organization","name":"MGC Mutua","alternateName":"MGC","url":"https:\/\/www.mgc.es\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.mgc.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.mgc.es\/wp-content\/uploads\/2020\/03\/mgcmutua_h2_2t_reduccions.png","contentUrl":"https:\/\/www.mgc.es\/wp-content\/uploads\/2020\/03\/mgcmutua_h2_2t_reduccions.png","width":303,"height":165,"caption":"MGC Mutua"},"image":{"@id":"https:\/\/www.mgc.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/mgcmutua","https:\/\/x.com\/mgcmutua","https:\/\/www.youtube.com\/c\/MGCMutua"]},{"@type":"Person","@id":"https:\/\/www.mgc.es\/#\/schema\/person\/010c961d9c9acf38f11187a02b646c16","name":"Revista Inter\u00e8s Mutu","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/52302d684339b9d7bf5691e2ad00835d62ce3b4a435f21ca9f21fbe39c63cb1b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/52302d684339b9d7bf5691e2ad00835d62ce3b4a435f21ca9f21fbe39c63cb1b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/52302d684339b9d7bf5691e2ad00835d62ce3b4a435f21ca9f21fbe39c63cb1b?s=96&d=mm&r=g","caption":"Revista Inter\u00e8s Mutu"}}]}},"_links":{"self":[{"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/posts\/30903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/comments?post=30903"}],"version-history":[{"count":4,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/posts\/30903\/revisions"}],"predecessor-version":[{"id":30908,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/posts\/30903\/revisions\/30908"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/media\/30901"}],"wp:attachment":[{"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/media?parent=30903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/categories?post=30903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mgc.es\/ca\/wp-json\/wp\/v2\/tags?post=30903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}